Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 10 Recurrence 6 Lymphoma, Large B-Cell, Diffuse 5 Lymphoma, B-Cell 5 Lymphoma 5 Neoplasms 1 Immunoblastic Lymphadenopathy 1 Cytokine Release Syndrome 1 Aggression 1

Interventions

vandetanib 1 midostaurin 1 glofitamab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Aggression × glofitamab × Clear all

NCT06534437 2025-09-29

JASPIS-01

Ryvu Therapeutics SA

Phase 2 Recruiting

Aggression, Lymphoma, Non-Hodgkin, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡